Loading…
Loading…
New York, New York--(Newsfile Corp. - October 21, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened?
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.
U.S. stocks were mostly lower, with the Nasdaq Composite falling around 200 points on Wednesday.
Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.
MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered into a global settlement agreement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA® (treprostinil) inhalation powder will remain available to patients with PAH without disruption.
Liquidia Corporation (LQDA) Securities Investigation Notice - Levi and KorsinskyPR NewswireNEW YORK, Oct. 12, 2026Liquidia shareholders took a roughly 57% loss af